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Abstract
Organoid cultures are increasingly used to model human cancers experimentally with a view to tailoring personalized
medicine and predicting drug responses. Breast cancer is no exception, but in particular, primary breast cancer poses
some inherent difficulties due to the frequent presence of residual non-malignant cells in the biopsies. We originally
developed an assay for the distinction between malignant and non-malignant structures in primary breast cancer
organoid cultures (Petersen et al., Proc Natl Acad Sci (USA) 89(19):9064–8, 1992). Here, we apply this assay to assess
the frequency of normal-like organoids in primary breast carcinoma cultures and the cellular composition as a
consequence of passaging. We find that in consecutively collected samples of primary human breast cancers, residual
non-malignant tissues were observed histologically in five out of ten biopsies. Based on relevant morphogenesis and
correct polarization as recorded by expression in luminal epithelial cells of mucin 1 (Muc1), occludin, and keratin 19
(K19) and expression in basal cells of integrin β4, p63, and K14, non-malignant organoids were present in all primary
human breast cancer-derived cultures. Furthermore, passaging in a contemporary culture medium was in favor of the
selective expansion of basal-like cells. We conclude that organoid cultures of human breast cancers are most
representative of the tissue origin in primary culture.
Keywords: Breast cancer, Organoids, Phenotypic drifting
Introduction
Organoid culture conditions have been devised for mul-
tiple human cancer types including those of the colon,
esophagus, pancreas, stomach, liver, endometrium, pros-
tate, and breast (for review, see [1]). Recently, a recipe
based on a key addition of Neuregulin-1 to the culture
medium allowed for the culture of > 80% of human
breast cancer biopsies. In a preliminary characterization
of the breast cancer organoids, some were passaged for
> 20 passages [2]. A total of 95 “lines” were obtained, but
in general, the identity of the cultured cells was not ob-
vious. Previous attempts to, for example, predict drug
response by using 2D or 3D primary cell culture models
of cancer have been complicated by the potential con-
current growth of cells from residual, non-malignant
tissue ([3, 4]; for reviews, see [5–7]). As far as breast
cancer is concerned, a solution to this problem was
offered by defining the reproducible behavior of normal-
like and non-malignant cells in 3D organoid assays
([8–10]; for review, see also [11]). Here, we use this assay
to assess how often non-malignant tissue contributes to
organoid culture within a sample of primary breast cancer
and how this affects the outcome of the culture if
passaged.
Methods
Tissue collection
Normal breast biopsies were collected from seven
healthy women undergoing reduction mammoplasty for
cosmetic reasons and ten women undergoing mastec-
tomy for primary breast cancer. Donors were informed
before the surgery and agreed by written consent to
donate tissues. The use of human material has been
reviewed by the Regional Scientific Ethical Committees
(Region Hovedstaden, with reference to H-2-2011-052,
H-2-2010-051, and H-3-2010-095). The permit for
obtaining clinical material did not include access to basic
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information regarding patients, and their detailed med-
ical histories are not given to the authors. Normal breast
biopsies were processed and frozen as organoids as
previously described [12], while tumor biopsies were
processed immediately upon receipt and cultured as de-
scribed below.
Organoid cultures
To obtain organoid cultures from normal myoepithelial
or luminal cell populations (n = 4 biopsies), frozen orga-
noids were thawed, trypsinized, and sorted as previously
described [13]. For single-cell plating, cells were FACS-
sorted using antibodies against the epithelial marker
Trop2 and the myoepithelial marker CD271 (modified
from [13]) (Additional file 1). Freshly sorted luminal and
myoepithelial cells were counted, and 5 × 104 cells were
embedded in 100 μl ice-cold Matrigel (Cultrex growth
factor reduced BME type 2, Trevigen) in 24-well plates.
After solidification of the Matrigel, 350 μl breast cancer
organoid medium ([2] and Additional file 2) was added,
and cells were kept at 37 °C and 5% CO2. The medium
was changed every 3–4 days.
For intact organoids, we used either fresh tissue or
freshly thawed organoids which were first pipetted up
and down repeatedly to reduce the size as described in
[2]. Next, these untrypsinized organoids were embedded
in 30 or 80 μl Matrigel depending on the tumor volume.
After solidification of the Matrigel-cell solution in 24-
well plates, breast cancer organoid medium was added
[2] and the medium was changed every 4 days. The
medium composition as well as information on the cul-
ture conditions is summarized in Additional files 2 and
3. Organoids were harvested for immunostaining after 2
to 4 weeks. Organoids were trypsinized and passaged ap-
proximately every 14–21 days.
Immunohistochemistry
Organoid cultures were frozen in n-hexane and
mounted for cryostat sections (6–8 μm). Cryostat sec-
tions were prepared and stained by immunofluorescence
Fig. 1 Organoid cultures derived from luminal and myoepithelial cells give rise to lineage-restricted organoids. (Top) FACS diagram of the sorting
strategy leading to isolation of pure luminal epithelial and myoepithelial cell populations using epithelial marker Trop2 and myoepithelial marker
CD271. (Middle) Phase-contrast micrographs of representative primary normal breast organoids from luminal epithelial and myoepithelial cells. A
total of 79 and 90 organoids derived from luminal and myoepithelial cells were evaluated (n = 4 biopsies). (Bottom) Representative fluorescence
micrographs of cryostat sections from luminal- (left) and myoepithelial-derived organoids (right) stained for either K19-AF568, K14-AF488, and
DAPI or Muc1-AF568, integrin β4-AF488, and DAPI
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as previously described [13] (Additional file 1). The
staining results were quantified either by manual cell
counting or by automatic cell counting using the open-
source image processing program, Fiji [14].
Statistical analyses
Percentages of K19+ and K14+ cells in the cryostat sec-
tions from primary biopsies were assessed by measuring
four different, randomly chosen areas of K19 and K14
staining, respectively, using Fiji and normalizing to the
total cell numbers by dividing it with the area of the nu-
clear stain in the same area. To assess the numbers of
malignant vs non-malignant organoids in organoid cul-
tures, these organoids were counted manually in stained
organoid sections (> 5 cells per organoid and 4 to 56
organoids per section). Organoids were counted as non-
malignant if they showed polarized K14+/K19+/− or integ-
rin β4+/Muc1+/− staining, while malignant organoids were
those that were only K19+ or Muc1+. The statistical ana-
lysis, including normal distribution and t test, was per-
formed by a statistical analysis program R (version 3.5.3).
Whole-genome sequencing
Genomic DNA was isolated from three pairs of primary
tumor samples and their organoids in passages 3 and 4,
using the DNeasy Blood and Tissue kit (Qiagen).
Whole-genome sequencing and its bioinformatics ana-
lysis were performed by BGI Tech Solutions (Hong
Kong). In short, 1 μg Genomic DNA per sample was
used for short-insert fragment (an average 350 bps) li-
brary preparation with BGISEQ in-house master mix.
The libraries were sequenced with pair-end 150 bp runs
using the BGISEQ-500 platform, and high-throughput
sequencing was performed in each library with 30×
depth per sample. Raw image files were processed by
BGISEQ-500 base-calling software and Genome analysis
Toolkit (GATK) (https://www.broadinstitute.org/gatk/
guide/best-practices) for variant analysis [15]. Total
clean data were mapped to the human reference genome
GRCh37/HG19, using Burrows-Wheeler Aligner [16].
On average, 99.9% mapped successfully and 92% mapped
uniquely with an average 44-fold sequencing depth on
the whole genome.
Local realignment around indels and base quality score
recalibration were performed using GATK with dupli-
cate reads removed by Picard tools (http://broadinsti
tute.github.io/picard/). The sequencing depth and cover-
age for each individual were calculated based on the
alignments. The genomic variations, including single nu-
cleotide polymorphisms (SNPs) and indels, were de-
tected by HaplotypeCaller of GATK (v3.3.0). The variant
quality score recalibration (VQSR) method, which uses
machine learning to identify the annotation profiles of
variants that are likely to be real, was applied to get
high-confident variant calls. The copy number variants
(CNVs) were detected using the CNVnator (v0.2.7), a
read-depth algorithm [17]. IGV (https://software.broad
institute.org/software/igv/), Gitools (http://www.gitools.
org/), and Clinvar (https://www.ncbi.nlm.nih.gov/clin
var/) programs were used for the visualization of genes
commonly mutated in breast cancer (COSMIC, https://
cancer.sanger.ac.uk/cosmic [18]).
Results
Behavior of normal myoepithelial cells and luminal
epithelial cells in organoid culture
We first examined how normal human breast epithelial
cells from four different reduction mammoplasties
responded to a breast cancer culture medium con-
taining the essential components of Neuregulin-1 and
the ROCK inhibitor Y-27632 [2]. For this purpose, we
initially aimed for optimal separation of normal lu-
minal epithelial and myoepithelial cells by a FACS-
based protocol relying on a combination of antibodies
against the EpCAM family-related trophoblast surface
antigen 2, Trop2, and the nerve growth factor recep-
tor, CD271 (Fig. 1). Upon plating inside the breast
cancer organoid assay as single cells, luminal cells
grew up to form approximately 50-μm-sized acinus-
like structures before growth arrest while myoepithe-
lial cells formed larger ball-like structures, both rem-
iniscent of what has been described originally with
another culture medium (Fig. 1 and [8]). To provide
further evidence for the presence of non-malignant
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Fig. 2 Normal-derived intact organoids in culture resemble in situ
normal breast biopsies. Representative fluorescence micrographs of
cryostat sections from normal breast biopsies (top) and normal
breast organoids (bottom) stained for either K19-AF568, K14-AF488,
and DAPI (left) or Muc1-AF568, integrin β4-AF488, and DAPI (right).
Note that organoids in the culture retain a
double-layered organization
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cells in the organoid assay, we sectioned and stained
the gels with markers of polarity and basement mem-
brane deposition. As seen in Fig. 1, while the acinus-
like luminal-derived structures resembled correctly
polarized acini with Muc1 expressed towards a central
lumen, both luminal and myoepithelial structures
stained with β4 integrin at the cell-extracellular
matrix (ECM) junction—a hallmark of non-malignant
behavior (Fig. 1 and [8]). This is in contrast to malig-
nant lesions. Thus, while about 50% of basal-like
breast cancers exhibit staining with β4 integrin, this is
focal and mostly unpolarized [19].
Since primary culture organoid assays often rely on
embedding untrypsinized organoids, we also examined
how luminal epithelial and myoepithelial cells behaved
if not trypsinized and sorted prior to plating. As seen
in Fig. 2, under this condition, the normal organoids
remained correctly polarized and organized in a
double-layered manner reminiscent of this in vivo
organization. Even if left to grow for weeks in culture
Fig. 3 Tumor-derived primary organoid cultures consist of normal-like and cancer-like organoids. a Representative fluorescence micrographs of
cryostat sections from breast cancer biopsies in situ (top) and corresponding representative tumor-derived organoids (bottom) stained for either
K19-AF568, K14-AF488, and DAPI (left) or Muc1-AF568, integrin β4-AF488, and DAPI (right). b Quantification of immunostaining of in situ profiles
and organoids. (Top) While in situ K14+ cells are relatively rare and almost always part of non-malignant profiles, they dominate in derived
organoid cultures. The opposite relation is seen as far as K19+ only cells are concerned. Data are presented as the mean percentage ± SD of the
areas positive for K14 or K19 in situ normalized by nuclear staining or the mean percentage ± SD of organoid numbers positive for K14 or K19.
(Bottom) Comparison of the numbers of organoids positive for integrin β4 (ITGB4) vs Muc1. Data are presented as the mean percentage ± SD of
the organoid numbers. Five independent tumor samples are examined for the analysis, and indicated p values are tested by t test
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as mainly conveyed by the outer layer of cells, this
bi-layered configuration remained intact in all profiles
examined and as such remained a breast-specific be-
havior of non-malignant organoids.
Breast cancer-derived organoid cultures
In order to distinguish breast cancer-derived organoids
from normal breast organoids in culture, we took advan-
tage of the unique breast-specific pattern described
above for normal cells; that by definition, non-
malignant/benign epithelial components comprise an
outer layer of K14 and integrin β4-positive myoepithelial
cells. In contrast, essentially, all nests of malignant cells
as they present themselves in situ are devoid of such a
layer [4]. By using this criterion and based on staining of
multiple sections, we found that non-malignant epithe-
lial profiles comprised only a minority (2.06 ± 1.5%) as
compared to malignant cells (79.6 ± 37%, p < 0.01)
(Fig. 3a, upper panel of in situ). As inferred by Sachs
et al. [2], primary organoid culture of such carcinomas
indeed captured the mixed composition of the tumor of
origin here demonstrated by the presence of both
double-layered non-malignant-like structures as well as
nests of unpolarized tumor-like cells devoid of myoe-
pithelial cells (Fig. 3a, lower panel of organoid culture).
This observation was further substantiated by apical
staining with ZO-1 and occludin against tight junction
proteins, which is either absent or perturbed in cancer
([10], reviewed in [20]). Furthermore, we found that the
specific myoepithelial marker p63, which is very rare in
breast cancer, clearly stained some organoids (Add-
itional file 4). In contrast, the estrogen receptor, which is
often present in primary tumors, did not stain in orga-
noids (data not shown). At the end of the primary cul-
ture period (2 to 4 weeks), the cultures consisted of both
cancer-like and normal-like/benign profiles (78.9% non-
malignant-like profiles, p < 0.001) (Fig. 3b). This was
interpreted in favor of all primary carcinomas containing
non-malignant, residual components albeit in such rela-
tively low numbers that they sometimes escape in situ
histological identification.
Since in primary culture luminal cells remained K19+
and K14−, we used this criterion to also identify cancer
cells upon passaging in organoid cultures. We passaged
the primary organoids by trypsinization into single cells
after 2 weeks and kept them for another additional
2 weeks in the second passage. Some were passaged fur-
ther to third and fourth passages. Indeed, the assay sup-
ported the growth of single cells recovered from the
trypsinization of primary organoids. Thus, the second to
fourth passage organoids grew up to form solid ball-like
structures. However, staining of K14 and integrin β4 as
well as other myoepithelial/basal keratins K5 and K17
revealed a composition similar to that of the basal layer
of myoepithelial cells as described above from flow-
sorted reduction mammoplasties (Fig. 4). In none of the
passaged organoid cultures, the growth of luminal-like
cells was recorded by the staining criteria used (Fig. 4).
These data are in favor of some drifting of the collective
phenotype of the culture. Whether this is echoed in the
overall genomic drifting was assessed by whole-genome
sequencing of three paired samples of tumors and third/
fourth cultures. As seen in Fig. 5, the landscape of copy
number variations among the selected candidate breast
cancer driver genes in general underwent a change to-
wards a dilution of the in vivo genomic aberrations. This
can only arise as a consequence of a selection of less ab-
errant cells during organoid cultures. That these never-
theless exhibit substantial genomic copy number
alterations is not incompatible with a potential non-
malignant or benign origin from uninvolved breast tissue
of breast carcinomas [21]. Since most breast cancer pre-
disposition loci are present already at the level of ductal
carcinomas in situ (DCIS [22];), we also screened for
breast cancer-associated single nucleotide variations. In-
deed, the fact that we find examples of culture-induced
“normalizations” of single nucleotide variations suggests
the selection in the culture of clones upstream of DCIS
cells (Fig. 5).
Collectively, we conclude that organoid cultures of hu-
man breast cancer drift upon passaging of the cells
Fig. 4 K14+/ITGB4+ cells dominate in tumor-derived organoid
cultures after passaging. Representative fluorescence micrographs of
cryostat sections from tumor-derived organoids in passage 2 or 3
stained for K19-AF568/K14-AF488 (upper left), Muc1-AF568/integrin
β4-AF488 (upper right), K5-AF488 (lower left), and K17-AF488 (lower
right). The nuclei were stained with DAPI. Scale bar, 50 μm
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which may confound predictions based on drug screens
in such cultures.
Discussion
Here, we reappraise the complicated technology of orga-
noid culturing of human breast cancer by combining
early measures to identifying the organoids with a con-
temporary recipe for long-term culture. We provide evi-
dence that fidelity in terms of resemblance between
tissue and culture is highest in the early passage. In the
present study, we failed to establish permanent cell lines
from primary human breast cancer even with this new
recipe. This may be because our material was limited to
10 biopsies. We and others, however, have previously
shown that successful long-term culture of human breast
cancer is a relatively rare event in the order of 1 out of
30 biopsies [4, 23]. Most success is obtained with basal-
like breast cancer-derived cultures and certain metastatic
lesions. This appears also to apply to the new recipe
medium relying on a large material where those of the
organoid cultures qualifying for the in vivo drug testing
were all grade 3 ER-negative (10 T), basal-like derived
(27 T), or from metastatic lesions (33 T and 213 T) [2].
However, even more importantly, what contributes to
the complexity in particular of primary breast cancer
organoid culture is the almost omnipresence of residual,
non-malignant tissue. In this respect, it is worthwhile
noticing that inclusion of Neuregulin-1 in the medium is
probably not the answer to specific growth requirements
of cancer cells. Rather, Neuregulin-1 has been shown to
extend the growth of normal mammary organoids [24].
It could be argued that the same markers that we use
here to claim non-malignancy, e.g., β4 integrin and kera-
tin K5, in a cancer context are used as markers of
Fig. 5 Genomic aberrations in primary tumors and corresponding organoids. Representations of copy number variations (a), indels (b), and
clinically relevant SNPs (c) of driver oncogenes and tumor suppressor genes relevant to breast cancer. Genomic DNAs of primary tumors (T) and
corresponding organoids (O) from three different patients (P1100, P1116, P1117) were analyzed by whole-genome sequencing (detailed
information in the “Methods” section). Represented SNPs (black boxes) are PIK3CA (RCV000024623.6, RCV000154512.1, RCV000201232.1), PTEN
(RCV000008256.2, RCV000008257.2, RCV000128455.2, RCV000162649.3, RCV000212882.1), RUNX2 (RCV000177104.2), and BMPR1A (RCV000034703.1,
RCV000120253.2, RCV000131909.2). Note that organoids show different or much less genomic aberrations compared to primary tumors
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subsets of cancer cells with EMT or stem-like properties
[19, 25]. However, β4 integrin stains one third of breast
cancer biopsies only [19], and we had no basal-like
breast cancers stained with β4 integrin among tumor
cells in our sample. We further note that unlike the typ-
ical basal staining that we see in non-malignant tissue,
when seen at the surface of cancer cells, β4 integrin is
very rarely polarized correctly [19]. Therefore, our obser-
vation of a strong polarized staining at the cell-ECM
junction of the organoids in passaged cultures is in favor
of a non-malignant or benign origin. A similar logic is
applicable to staining with the two other markers keratin
K5 and K17. Thus, in contrast to the uniform staining of
non-malignant tissue, when present in basal-like cancer,
K5 and K17 mostly appear in scattered single cells. Ac-
cordingly, the widespread staining with basal keratins in
profiles of the cultured organoids points towards a non-
malignant origin.
Finally, it is important to appreciate the limitations of
genomics in deciding between malignant and non-
malignant since apparently uninvolved breast tissue from
breast cancer patients shows many of the same aberra-
tions as the cancer itself [21], and the majority of prema-
lignant lesions resemble invasive cancer by the
mutational profile [22].
Collectively, these considerations underscore that
using human breast organoid culture for clinical pur-
poses should if at all be restricted to primary culture.
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